We are live on
!
Find out more
KAM
Kazazian Asset Management Portfolio holdings
AUM
$111M
1-Year Est. Return
29.02%
This Fund
S&P 500
This Quarter
Est. Return
+7.54%
1 Year Est. Return
+29.02%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$81.7M
AUM Growth
+$15.6M
(+24%)
Cap. Flow
+$11.7M
Cap. Flow
% of AUM
14.33%
Top 10 Holdings %
Top 10 Hldgs %
57.21%
Holding
75
New
23
Increased
16
Reduced
5
Closed
5
Avg Time Held
3.8
quarters
Top 10 Avg Time Held
6.5
quarters
Top 20 Avg Time Held
5
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$1.33M |
| 2 |
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
|
+$933K |
| 3 |
Vertex Pharmaceuticals
VRTX
|
+$879K |
| 4 |
Chipotle Mexican Grill
CMG
|
+$876K |
| 5 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$719K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI Brazil ETF
EWZ
|
+$888K |
| 2 |
Perrigo
PRGO
|
+$529K |
| 3 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$387K |
| 4 |
Global X MSCI Greece ETF
GREK
|
+$365K |
| 5 |
SGEN
Seagen Inc. Common Stock
SGEN
|
+$354K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 27.62% |
| 2 | Healthcare | 26.95% |
| 3 | Consumer Discretionary | 11.94% |
| 4 | Financials | 11.46% |
| 5 | Communication Services | 8% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
iShares MSCI Emerging Markets ETF
EEM
$31B
| $9.19M | 11.24% |
205,000
+10,000
| +5% | +$440K |
2017 Q2
1 quarter
|
|
|
2
State Street SPDR S&P 500 ETF Trust
SPY
$833B
| $7.43M | 9.1% |
29,584
-1,570
| -5% | -$387K |
2015 Q1
10 quarters
|
|
3
General Motors
GM
$72.6B
| $7.16M | 8.76% |
177,204
| – | – |
2014 Q4
11 quarters
|
|
4
DELISTED
DigitalBridge
DBRG
| $5.54M | 6.78% |
110,318
| – | – |
2017 Q1
2 quarters
|
|
5
Alphabet (Google) Class C
GOOG
$4.25T
| $3.67M | 4.5% |
76,640
| – | – |
2014 Q4
11 quarters
|
|
6
Citigroup
C
$217B
| $3.67M | 4.49% |
50,431
| – | – |
2014 Q4
11 quarters
|
|
|
7
Biogen
BIIB
$33.3B
| $3.29M | 4.02% |
10,501
+4,500
| +75% | +$1.33M |
2016 Q2
5 quarters
|
|
|
RESI
8
DELISTED
Front Yard Residential Corporation Common Stock
RESI
| $2.39M | 2.92% |
214,925
| – | – |
2015 Q3
8 quarters
|
|
9
Apple
AAPL
$4.91T
| $2.32M | 2.84% |
60,280
| – | – |
2014 Q4
11 quarters
|
|
10
iShares Silver Trust
SLV
$29.5B
| $2.08M | 2.55% |
132,300
-5,000
| -4% | -$79.7K |
2016 Q2
5 quarters
|
|
11
iShares MSCI Germany ETF
EWG
$1.46B
| $1.78M | 2.18% |
55,000
| – | – |
2017 Q2
1 quarter
|
|
12
DELISTED
Blueprint Medicines
BPMC
| $1.72M | 2.11% |
24,735
+1,462
| +6% | +$78.1K |
2017 Q2
1 quarter
|
|
13
Baidu
BIDU
$29B
| $1.54M | 1.89% |
6,229
| – | – |
2015 Q3
8 quarters
|
|
14
Alibaba
BABA
$277B
| $1.5M | 1.84% |
8,703
+243
| +3% | +$39.4K |
2014 Q4
11 quarters
|
|
|
ALXN
15
DELISTED
Alexion Pharmaceuticals
ALXN
| $1.49M | 1.82% |
10,614
+3,891
| +58% | +$529K |
2017 Q1
2 quarters
|
|
|
CLVS
16
DELISTED
Clovis Oncology, Inc.
CLVS
| $1.44M | 1.76% |
17,493
+6,229
| +55% | +$494K |
2017 Q2
1 quarter
|
|
17
Bristol-Myers Squibb
BMY
$121B
| $1.42M | 1.74% |
22,344
+7,137
| +47% | +$417K |
2017 Q1
2 quarters
|
|
18
Bausch Health
BHC
$2.26B
| $1.11M | 1.36% |
77,311
| – | – |
2015 Q4
7 quarters
|
|
19
People Inc
PPLI
$3.04B
| $1.1M | 1.35% |
52,323
| – | – |
2014 Q4
11 quarters
|
|
20
VanEck Gold Miners ETF
GDX
$26.7B
| $939K | 1.15% |
40,881
-3,000
| -7% | -$69.3K |
2015 Q3
8 quarters
|
|
|
21
Vertex Pharmaceuticals
VRTX
$129B
| $887K | 1.09% |
+5,837
| New | +$879K |
2017 Q3
0 quarters
|
|
22
Aurinia Pharmaceuticals
AUPH
$2.22B
| $877K | 1.07% |
139,937
+73,633
| +111% | +$464K |
2017 Q1
2 quarters
|
|
|
JUNO
23
DELISTED
Juno Therapeutics, Inc.
JUNO
| $866K | 1.06% |
19,301
+4,994
| +35% | +$170K |
2017 Q2
1 quarter
|
|
24
Micron Technology
MU
$1.16T
| $826K | 1.01% |
21,000
-4,000
| -16% | -$126K |
2014 Q4
11 quarters
|
|
|
25
Chipotle Mexican Grill
CMG
$40B
| $800K | 0.98% |
+130,000
| New | +$876K |
2017 Q3
0 quarters
|
|
Similar funds
FF
VR
WCBA
CCM
LA
MASM
PFG
RM
Kazazian Asset Management's Q3 2017 Portfolio in Review
As of Q3 2017, Kazazian Asset Management held 75 positions worth $81.7M, up 24% from $66.1M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Kazazian Asset Management deployed $11.7M of net new capital in Q3 2017, opening 23 new positions and adding to 16 existing holdings. Its largest new stake was Intercept Pharmaceuticals, Inc.: 8,666 shares worth $503K.
By sector, the portfolio is most concentrated in Miscellaneous at 28% of assets, down from 34% a quarter earlier, followed by Healthcare and Consumer Discretionary.
On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $387K trimmed.
- Kazazian Asset Management's largest Q3 2017 buy was Intercept Pharmaceuticals, Inc.: 8,666 shares worth $503K.
- Kazazian Asset Management added most to Biogen in Q3 2017, an estimated $1.33M increase.
- Kazazian Asset Management's biggest Q3 2017 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $387K.
- Kazazian Asset Management fully exited iShares MSCI Brazil ETF in Q3 2017, selling an estimated $888K.
- Kazazian Asset Management's ten largest holdings make up 57% of its $81.7M portfolio in Q3 2017.
- Kazazian Asset Management opened 23 new positions and closed 5 in Q3 2017.
- Kazazian Asset Management's portfolio value rose 24% quarter-over-quarter to $81.7M.
Based on Kazazian Asset Management's 13F filing for Q3 2017, filed 14 Nov 2017.